Osseointegration surgery has a relatively short clinical history.
Multiple factors can affect the performance of an implant:
To remain at the forefront of innovation for all these elements, whilst remaining focussed on surgical aspects and patient care, Osseointegration International has developed a solid partnership with the global manufacturer Permedica Orthopaedics.
The joint research and development teams of Osseointegration International and Permedica guarantee that implants evolve with the latest improvements.
One of the benefits of this partnership is the clinically proven progressive improvement in clinical outcomes and the constant reduction of long-term complication rates
COMMITTED TO INNOVATION: Permedica specialises in 3D-printing manufacturing supporting Osseointegration International with customised implants when the amputee’s anatomy requires it.
The company is also investigating alternative surface coating and the use of antimicrobial nanoparticles for OPL.
The Osseointegration Group exists to enable amputees worldwide to improve their quality of life through the application of clincal expertise and technical and technological innovation.
The OPL Device is not approved for sale in the US. Please contact us for further information on device availability in your region. Information provided via this website is for educational and communication purposes only. The material presented represents techniques and procedures used by The Osseointegration Group (OG). OG disclaims any and all liability for injury and/or other damages which result from an individual using techniques presented on this website.